For-profit schools appear to be playing an outsized role in training the nation’s expanding nurse practitioner workforce, according to a study that found nearly one-third of newly licensed… read more.
Roche announced that the FDA has approved Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage… read more.
Three out of England’s seven NHS genetics laboratories are failing to routinely share vital information about genetic variants in public databases that helps patients with rare diseases access… read more.
Several reforms to EU chemicals policy and legislation have been introduced in recent years, with the aim of promoting the green transformation. Many of these reforms also affect… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved catumaxomab (Korjuny) to treat malignant ascites in adults when standard treatment of their cancer is no longer feasible…. read more.
Despite advances in technology, patients continue to face significant unmet medical need. This paradox should drive medicines regulators to rethink their role in the health system, according to… read more.
The European Medicines Agency (EMA) has recommended the approval of 12 new products at its September meeting. This brings the number of new medicines approved this year to… read more.
The European Medicines Agency (EMA) has launched a new voluntary data submission (VDS) pilot to facilitate the sharing of information generated using New Approach Methodologies (NAMs). These innovative… read more.
Starting in July 2029, public schools are required to start phasing out ultra-processed foods under a new California law that prohibits schools from serving foods high in sugar,… read more.
NICE(UK): Trastuzumab deruxtecan can be used, within its marketing authorisation, as an option to treat HER2-low metastatic or unresectable breast cancer in adults after: i) chemotherapy in the… read more.
NICE(UK): Isatuximab plus pomalidomide and dexamethasone can be used as an option to treat relapsed and refractory multiple myeloma in adults if: i) they have had 3 previous… read more.
Novocure announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, concomitant… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
